Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients

Annals of Pharmacotherapy

Volumn 40, Issue 9, 2006, Pages 1509-1516

  Ting, Lillian S L ^a   Partovi, Nilufar ^a,b   Levy, Robert D ^a,c,d,e   Riggs, K Wayne ^a   Ensom, Mary H H ^a,f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c British Columbia Transplant Society   (Canada)

^d VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^e The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research   (Canada)

^f CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Lung transplant; Mycophenolic acid; Pharmacokinetics

Indexed keywords

7 O MYCOPHENOLIC ACID ACYL GLUCURONIDE; 7 O MYCOPHENOLIC ACID GLUCURONIDE; ALBUMIN; CREATININE; CYCLOSPORIN; DRUG METABOLITE; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALPHA 1 ANTITRYPSIN DEFICIENCY; AMERICAN INDIAN; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BRONCHIOLITIS OBLITERANS; CAUCASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG METABOLISM; FEMALE; FIBROSING ALVEOLITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIVIDUALIZATION; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG GRAFT REJECTION; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; MALE; OPEN STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

ADULT; AGED; FEMALE; GLUCURONIDES; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 33748325846     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H149     Document Type: Article

References (31)

1. Eisen H, Ross H. Optimizing the immunosuppressive regimen in heart transplantation. J Heart Lung Transplant 2004;23:S207-13.
2. Gerbase MW, Fathi M, Spiliopoulos A. Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis. J Heart Lung Transplant 2003;22:587-90.
3. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002;8:40-6.
4. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004;75:434-47.
5. Package insert. Cellcept (mycophenolate mofetil). Nutley, NJ: Roche Laboratory, March 2003.
6. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-55.
7. Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem 2001;34:17-22.
8. Wieland E, Shipkova M, Shellhaas U, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 2000;33:107-13.
9. Schutz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 1999;45:419-22.
10. Shipkova M, Wieland E, Schutz E, et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 2001;33:1080-1.
11. Shaw LM, Holt DW, Oellerich MO, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001;23:305-15.
12. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68:261-6.
13. Kuriata-Kordek M, Boraynska M, Falkiewicz K, et al. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. Transplant Proc 2003;35:2369-71.
14. Barten MJ, Shipkova M, Bartsch P, et al. Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo. Ther Drug Monit 2005;27:123-31.
15. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolic mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000;14:100-4.
16. Pillans PI, Rigby RJ, Kubler P, et al. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem 2001;34:77-81.
17. Krumme B, Wollenberg K, Kirste G, Schollmeyer P. Drug monitoring of mycophenolic acid in the early period after renal transplantation. Transplant Proc 1998;30:1773-4.
18. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Res J 2004;23:159-71.
19. Akioka K, Takahara S, Ichikawa S, Yoshimura N, Akiyama T, Ohshima S. Factors predicting long-term graft survival after kidney transplantation: multicenter study in Japan. World J Surg 2005;29:249-56.
20. Ensom MHH, Partovi N, Decarie D, Dumont RJ, Fradet G, Levy RD. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. Ther Drug Monit 2002;24:310-4.
21. Ensom MHH, Partovi N, Decarie D, Ignaszewski AP, Fradet GJ, Levy RD. Mycophenolate pharmacokinetics in early period following lung or heart transplantation. Ann Pharmacother 2003;37:1761-7. DOI 10.1345/aph.1D099
22. David-Neto E, Pereira LM, Kakehashi E, et al. The need of mycophenolic acid monitoring in long-term renal transplants. Clin Transplant 2005; 19:19-25.
23. DeNofrio D, Loh E, Kao A, et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 2000;19:1071-6.
24. Jain A, Venkataramanan R, Hamad IS, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001;41: 268-76.
25. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003;25:609-22.
26. Kuypers DR, Claes K, Evenepoel P, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003;43:866-80.
27. Pisupati J, Jain A, Burckart G, et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005;45:34-41.
28. Daudén E, Sánchez-Peinado C, Ruiz-Genao D, Garcia-F-Villalta M, Onate MJ, Garcia-Diez A. Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis. Br J Dermatol 2004;150:132-5.
29. Deters M, Kirchner G, Koal T, Resch K, Kaever V. Influence of cyclosporine on the serum concentration and biliary excretion of mycophenolic acid and 7-O-mycophenolic acid glucuronide. Ther Drug Monit 2005;27:132-8.
30. Holt DW. Monitoring mycophenolic acid. Ann Clin Biochem 2002; 39:173-83.
31. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006;28: 145-54.